



To:

THE DIRECTOR GENERAL OF HEALTH SERVICES IN ALL GOVERNORATES
Commanding Officer, Armed Forces Hospital (Al Khoudh & Salalah)
Director General of Engineering Affairs, MOH
Director General of Royal Hospital
Director General of Khoula Hospital
Director General of Medical Supplies (MOH)
Director General of Pvt. Health Est. Affairs (to kindly arrange distribution to all Pvt. Hospitals)
Hospital Director (Al Nahda Hospital)
Hospital Director (Al Massara Hospital)
The Head of Medical Services in SQU Hospital
The Head of Medical Services in Royal Oman Police
The Head of Medical Services in Ministry of Defence
The Head of Medical Services in The Diwan
The Head of Medical Services in The Sultan's Special Force
The Head of Medical Services in Internal Security Services
The Head of Medical Services in Petroleum Development of Oman
The Head of Medical Services in LNG Oman
ALL PRIVATE PHARMACIES & DRUG STORES

After Compliments,

Please find attached our Circular No. 259. dated 30/11/23 Regarding NCMDR recall of BD™ CD11b APC, CE from (mfr: BD Switzerland Sarl).

Copy to:

- Director, Office of H.E. The Undersecretary for Health Affairs
- Director of Medical Device Control, DGPA&DC
- Director of Pharmacovigilance & Drug Information Dept, DGPA&DC
- Director of Drug Control Department, DGPA&DC
- Director of Pharmaceutical Licensing Department, DGPA&DC
- Director of Central Quality Control Lab., DGPA&DC
- Supdt. of Central Drug Information





Circular No. 259 / 2023

16 -05-1445 H

30 -11-2023

نتقدم بثقة
Moving Forward
with Confidence



Recall of BD™ CD11b APC, CE from BD Switzerland Sarl .

Source	NCMDR- National Center for Medical Devices Reporting- SFDA https://ncmdr.sfda.gov.sa/Secure/CA/CaViewRecall.aspx?caid=4&rid=19751
Product	BD™ CD11b APC, CE.
Description	In vitro diagnostic devices.
Manufacturer	BD Switzerland Sarl.
Local agent	Mustafa Sultan Science & Industry Co.LLC.
The affected products	Product Code (REF): 333143 Lot Number: 3114710 Expiry Date: 28 Feb 2025 UDI-DI: (01)00382903331437
Reason	It has confirmed through customer complaint investigations that the above affected lot of the product has low or dim fluorescence signal reported.
Action	1. If the affected lot was used in testing of patient samples, review the results of the lot validation testing to identify if the intensity of staining was appropriate, and review the patient results for accuracy and consider other diagnostic tests, if necessary. 2. Inspect your inventory, identify, quarantine, and destroy any units of the above affected. 3. Contact the local agent for remedial action.
comments	Healthcare professionals are encouraged to report any adverse events Suspected to be associated with the above device or any other medical device to Department of Medical Device Control through the E-mail: Med-device@moh.gov.om

Dr. Mohammed Hamdan Al Rubaie
Director General

